• Open-label studies preferable to double-blind parallel trials for childhood SLE treatments

    12 days ago - By Healio

    To increase the speed with which new treatments for childhood-onset systemic lupus erythematosus are studied, researchers should look to specialized networks and trial designs successfully used in other rare diseases, according to a review published in the Annals of the Rheumatic Diseases.
    In addition, the researchers concluded that open-label pharmacokinetic-pharmacodynamic studies, rather than double-blind parallel designs, are preferred by pediatric rheumatology investigators for childhood-onset SLE trials.
    “There are no drugs that have been approved by either FDA or [European
    Read more ...